• Underlying EBITDA up 8.1% to $258.6 million
• Underlying EBIT up 76.6% to $30.2 million
• Group revenue up 2.1% to $1.37 billion

Healius Ltd reported FY 2026 results showing underlying EBITDA up 8.1% to $258.6 million, underlying EBIT up 76.6% to $30.2 million, and group revenue up 2.1% to $1.37 billion. Pathology revenue grew by 1.8% and Agilex Biolabs revenue increased by 14.1%. The company experienced operational improvements, better second-half Pathology margins, and cost management. Healius remains focused on restoring sustainable margin and cash flow performance through revenue quality, network optimization, and technology-enabled productivity.

Healius expects FY 2027 EBIT to be in line with consensus at $39.7 million.

Healius expects to achieve mid-to-high single-digit EBIT margins by approximately December 2028, contingent on external factors like Fair Work costs and reduced GP attendances.